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Abstract
Background: Genome-wide association studies (gwas) are invaluable in revealing the common variants predisposing to
complex human diseases. Yet, until now, the large volumes of data generated from such analyses have not been explored
extensively enough to identify the molecular and functional framework hosting the susceptibility genes.
Methodology/Principal Findings: We investigated the relationships among five neurodegenerative and/or autoimmune
complex human diseases (Parkinson’s disease-Park, Alzheimer’s disease-Alz, multiple sclerosis-MS, rheumatoid arthritis-RA and
Type 1 diabetes-T1D) by characterising the interactomes linked to their gwas-genes. An initial study on the MS interactome
indicated that several genes predisposing to the other autoimmune or neurodegenerative disorders may come into contact
with it, suggesting that susceptibility to distinct diseases may converge towards common molecular and biological networks.
In order to test this hypothesis, we performed pathway enrichment analyses on each disease interactome independently.
Several issues related to immune function and growth factor signalling pathways appeared in all autoimmune diseases, and,
surprisingly, in Alzheimer’s disease. Furthermore, the paired analyses of disease interactomes revealed significant molecular
and functional relatedness among autoimmune diseases, and, unexpectedly, between T1D and Alz.
Conclusions/Significance: The systems biology approach highlighted several known pathogenic processes, indicating that
changes in these functions might be driven or sustained by the framework linked to genetic susceptibility. Moreover, the
comparative analyses among the five genetic interactomes revealed unexpected genetic relationships, which await further
biological validation. Overall, this study outlines the potential of systems biology to uncover links between genetics and
pathogenesis of complex human disorders.
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Introduction
The aim of genome-wide association studies (gwas) is to discover
the common genetic variants associated with susceptibility to
complex diseases. In a typical experiment, hundreds of thousands
of markers are tested simultaneously in cases and controls, and the
allelic frequencies of each marker in the two groups are compared,
so that the contribution of single genes to the disease is quantified.
However, complex diseases do not originate from changes in single
genes, but from the interactions between several genetic and
environmental factors. Therefore, the analysis of isolated genes is
not overly informative about the biological processes underlying
disease and offers limited rationale for the development of novel
therapies. Theoretically, reconstruction of the molecular interac-
tion networks linked to gwas-genes by systems biology approaches
may help to elucidate the functional consequences related to each
susceptibility allele and the combined effects of more genetic
variants. The few reports available to date on this issue
demonstrated that this approach can identify previously unseen
relationships among human diseases at molecular level [1,2].
In this study, we elaborated the genetic interactomes relative to
five complex human diseases. Our lab has strong interest in
multiple sclerosis (MS), a chronic disorder of the central nervous
system presumably of autoimmune etiology, characterized by
inflammation of the white matter, demyelination and neurode-
generation [3]. Initially, we reconstructed the MS interactome
and searched for interactions with genes predisposing to either
neurodegenerative (Parkinson’s disease Park, Alzheimer’s disease
Alz) or autoimmune (Type 1 diabetes T1D, Rheumatoid Arthritis
RA) disorders. Then, disease interactomes of all five disorders
were analyzed at the functional level by independent pathway
enrichment studies. Finally, paired comparisons elucidated
relatedness among the diseases. Interestingly, the shift from
single genes to molecular frameworks via system biology
unraveled novel functional relationships among the five complex
diseases.
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Link between the MS interactome and the genes
predisposing to other neurodegenerative or
autoimmune diseases
Initially we identified the susceptibility genes that were linked to
MS and to other neurodegenerative (Park, Alz) or autoimmune
(T1D, RA) disorders. We utilized results from 39 published
genome-wide association studies on these five human diseases
available in the GWAS catalog [4] and found genetic mutations in
179 genes passing the statistical significance threshold of 10
25
(Table 1). There were 6 studies available for MS, Park and RA, 8
for T1D, and 13 for Alz (Table S1). Notably, the number of studies
carried out for each disease did not seem to influence the total
number of disease-associated genes. For instance, despite the
highest number of genome-wide association studies performed for
Alz, the total number of susceptibility genes reported was the
lowest among the five diseases. The ratios between the number of
the reported genes and the number of studies in each disease
accounted for this observation (Table 1). Interestingly, MS
displayed the highest number of susceptibility genes and the
highest ratio, suggesting a greater genetic heterogeneity in MS
than in the other four diseases. Then, as a first step towards the
definition of the genetic network underlying these five diseases, we
reconstructed the MS genetic interactome and checked possible
links with the genes predisposing to the other neurodegenerative or
autoimmune diseases. Using the VisANT tool we derived 376 first-
degree interacting partners for the 54 MS gwas-genes. Among
these MS interactors, 141 were connected with at least one among
17 T1D, 11 RA, and 10 Park or Alz gwas-genes (Figure 1A and
Table S2). Notably, 4 MS interactors were RA (HLA-DQA1,
TRAF1) or T1D (IL2, PTPN11) gwas-genes themselves. It was
also evident that several gwas-genes could come into contact with
two or more MS interactors (Figure 1A), and that 24 MS
interactors were connected with both neurodegenerative and
autoimmune genes (red nodes in Figure 1A), including the
PTPN11 gene.
Now, the analysis of disease relatedness with MS is more
effective when considering the genetic interactome rather than
direct interactions at the gwas-gene level. In fact, no interactions
existed between gwas-genes predisposing to MS and Alz, for
example, but there were several shared interactions within the
genetic interactomes linked to (but not including) the respective
gwas-genes (Figure 1B). Therefore, the introduction of first-degree
interactors in the definition of a disease-related molecular
framework may lead to the discovery of relatedness among distinct
complex disorders.
Molecular relatedness among autoimmune and
neurodegenerative genetic interactomes
To perform a global comparative analysis among autoimmune
and neurodegenerative genetic interactomes, we derived a list of
interacting partners for each gwas-geneset (Table 2, Table S3). As
expected, the number of interactors was higher in MS and T1D,
due to the more abundant number of reported gwas-genes.
However, when normalizing the number of interactors to the total
number of gwas-genes in each disease, RA reported the highest
Table 1. Summary of gwas data.
MS Park Alz T1D RA Total
No. of studies 66 1 3 8 6 3 9
Unique genes 54 35 17 52 21 179
Gene/study
ratio
9 5.83 1.30 6.50 3.50 4.58
doi:10.1371/journal.pone.0018660.t001
Figure 1. Relationship between MS interactome and gwas genes relative to other diseases. A. MS interactors shared by genes
predisposing to neurodegenerative (green) and/or autoimmune (pink) diseases. Blue nodes indicate the MS interactors contacted by either
neurodegenerative or autoimmune susceptibility genes. Red nodes indicate the MS interactors contacted by both neurodegenerative and
autoimmune susceptibility genes. Note that four MS interactors are present among the T1D or RA gwas-genes. B. Comparison between MS and Alz at
gwas-gene and genetic interactome levels. Despite the absence of a direct interaction at gwas level, shared molecular networks appear in the genetic
interactomes (green section).
doi:10.1371/journal.pone.0018660.g001
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RA susceptibility genes were highly interactive. In contrast, Park
displayed the lowest interactor/gene ratio, despite the discrete
number of described gwas-genes.
Next, we examined the relationships among the five diseases by
comparing the genetic interactomes in a pairwise fashion. The
overlaps between interactomes are given in Table S4. Notably,
higher concordances were found among the autoimmune diseases,
with MS-RA, MS-T1D and T1D-RA having 84, 61 and 60
interactors shared respectively. Among the neurodegenerative
diseases, the sharing of interactors was limited to 10 elements for
Park-Alz, 20 for Park-MS and 25 for MS-Alz. Most surprisingly,
26 interactors were shared between the neurodegenerative Alz and
the autoimmune T1D. The statistical significances for these
observations were calculated using a hypergeometric test and are
shown in Figure 2 (see bars) and Table S5. MS-RA had the lowest
p-value (P=1.02E-67), followed by T1D-RA (P=4.42E-43) and
MS-T1D (P=3.09E-33). The T1D-Alz pair, with the p-value of
6.48E-19, was more significant than the MS-Alz pair (P=5.21E-
16). Comparatively higher p-values were found among T1D-Park
(P=1.18E-04), Alz-Park (P=8.72E-07), RA-Park (P=3.95E-07)
and MS-Park (P=3.36E-08), exhibiting the distant relatedness for
all possible combinations with Park (Figure 2). Altogether, the
results showed the close relatedness among autoimmune disorders
and within Alz pairs.
The degree of relatedness may be due to the real biological
properties of gwas-genes, i.e. the autoimmune gwas-genes
participate in more biological pathways and processes than the
neurodegenerative ones, and therefore the probability of abundant
interactor sharing among autoimmune diseases is higher. Howev-
er, we hypothesized that the observations could be partly biased by
the difference in the number of studies carried out on distinct
gwas-genes, consequently resulting in higher or lower interactor
information. To critically assess this aspect, we considered that the
average number of interactions per gene in the VisANT database
was equal to 7.26 (93684 interactions for 12888 human genes).
Consequently, we derived a normalization factor by normalizing each
disease interaction ratio to the one in the VisANT database (Table
S5). For example, the highest interaction ratio seen in RA resulted
in a normalization factor equal to 1.88, signifying a nearly two fold
increase in the interaction ratio compared to the database. Vice
versa, Park normalization factor was 0.71, indicating that the
interaction ratio was only 71% of that expected.
For paired analyses we multiplied the normalization factors relative
to the two diseases (see [materials and methods]), and used the
paired normalization factor to optimize the observed/expected ratio of
interactor sharing. This resulted in an interactor score for each
disease pair (Figure 2). So, if on the one hand the p-values relative
to the inter-disease relatedness may reflect the shared interactome
among diseases, on the other hand the interactor score might
flatten or enhance some of these observations as it corrects for
annotation bias. Therefore, both the p-values and the interactor
scores have to be considered while interpreting the results. The
interactor scores confirmed the close association among disease
pairs in the autoimmune group (Figure 2). Surprisingly, the highest
scores appeared in Alz-Park and T1D-Alz pairs. Therefore, even
after eliminating the possible bias introduced by database
annotation, the T1D-Alz pair maintained high association levels.
Biological themes in autoimmune and/or
neurodegenerative interactomes
In order to identify the biological themes embedded in each
interactome, we used the ToppGene suite, an online tool for
functional enrichment analysis. A Bonferroni corrected p-value of
0.05 was used to extract the significant biological pathways
reported by three distinct databases (CGAP-BioCarta, KEGG and
Panther). The highest number of pathways was reported in T1D
followed by MS, RA, Alz and Park respectively (Table S6).
Furthermore, we tabulated the shared pathways among diseases
and grouped them according to the database in seven main
categories: Growth factor/Hormone signaling, Innate/Adaptive immunity,
Cell cycle and apoptosis, Cancer, Adhesion, Host response and Other
(Figure 3). The combined statistical significance of the pathway
enrichments is also listed in Figure 3. The majority of shared
pathways were categorized in Growth factor/Hormone signaling,
followed by Innate/Adaptive immunity and Cell cycle and apoptosis,
Table 2. Genetic interactomes for neurodegenerative and/or
autoimmune disorders based on VisANT database.
Genes Interactors Interactor/gene ratio
Park 35 160 4.57
Alz 17 109 6.41
T1D 52 316 6.07
RA 21 249 11.85
MS 54 376 6.96
doi:10.1371/journal.pone.0018660.t002
Figure 2. Molecular relatedness based on shared interactome. Statistical significance for each paired analysis is given.
doi:10.1371/journal.pone.0018660.g002
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doi:10.1371/journal.pone.0018660.g003
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single databases.
In the Growth factor/Hormone signaling category, Panther indicated
EGF, FGF and PDGF signaling pathways as shared by three diseases,
Alz and T1D with MS or RA. The other pathways were shared
exclusively by autoimmune diseases, with the exception of
Angiogenesis that appeared both in T1D and Alz. In contrast to
Panther, KEGG evidenced predominant pathway sharing among
autoimmune disorders, except for the ErbB signaling present in Alz
and in the three autoimmune diseases. CGAP-BioCarta exposed
high concordances among Alz, T1D and MS. There were 10
pathways shared exclusively by these three diseases, among which
EGF signaling and PDGF signaling were already reported by the
Panther database. Many of the pathways common to these trios
were related to tyrosine kinase signaling, such as Trka receptor
signaling and Sprouty regulation of tyrosine kinases. Another remarkable
observation was the sharing of the NGF pathway by MS and Alz.
IGF-1 signaling, IL3 signaling, Insulin signaling and Growth hormone
signaling pathways were shared exclusively by T1D and Alz. In
addition, Park shared only three pathways with the autoimmune
diseases, namely Ceramide signaling, Trefoil factors initiate mucosal
signaling and Phosphoinositides and their downstream targets. Overall,
pathways shared by the five diseases in the Growth factor/Hormone
signaling category portrayed an undisputable association within the
autoimmune group with the predominant presence of T1D. It also
revealed that several biological themes related to tyrosine kinase
signaling were shared among Alz, T1D and MS. Most
unexpectedly, the analysis exposed numerous growth factor
related pathways common to T1D and Alz.
The second category Innate and adaptive immunity contained 20
pathways derived from the three pathway databases. Although
expected for autoimmune diseases, consistent sharing of immunity
related pathways was also found in Alz. For example, pathways
related to B and T cell activation appeared in all databases as
shared by T1D, RA, MS and Alz. Furthermore, in the KEGG
database Alz and T1D exclusively shared the Fc epsilon RI signaling
pathway and Natural killer cell mediated cytotoxicity pathway, whereas
CGAP-BioCarta emphasized predominant pathway sharing
between MS and RA.
In the third category, Cell cycle and apoptosis, Panther and KEGG
contributed with 2 pathways each, and Park shared the Apoptosis
signaling pathway with RA and MS. Among the CGAP-BioCarta
results, Alz shared 3 pathways with autoimmune diseases, while 4
pathways were shared exclusively by T1D-RA or RA-MS disease
pairs.
The fourth category contained pathways derived from the
KEGG database related to Cancer. It resulted that many genes
appearing in autoimmune and/or neurodegenerative interactomes
played a role in cancer related pathways.
In the fifth category (named Adhesion), the Focal adhesion pathway
(KEGG) was common to Park and the autoimmune group and the
Integrin signaling pathway (CGAP-BioCarta) was shared among
neurodegenerative disorders and T1D. In addition, the Adherens
junction pathway in KEGG was shared among Alz, T1D and MS.
The sixth category contained pathways related to Host response,
which was reported exclusively by the KEGG database. Park and
MS shared two pathways related to E. coli infection, and the
autoimmune diseases shared the Epithelial cell signaling in Helicobacter
pylori infection pathway. Lastly, the category Other contained the
Parkinson’s pathway reported by Panther, which was common to
Park and RA.
Overall, pathway analysis revealed predominant sharing of
functions among autoimmune diseases. Moreover, many of these
pathways appeared also in Alz, which was associated with T1D in
most cases.
Quantitative analysis of functional relatedness among
neurodegenerative and autoimmune interactomes
We tabulated the shared pathways for all disease pairs (Table
S7) and quantified the significance of observed pathway overlaps
by performing a hypergeometric test for each database separately
(Figure 4A). According to Panther, the most significant pathway
overlap was in the T1D-Alz pair (P=2.10E-07), followed by the
T1D-RA (P=1.48E-05) and the RA-Alz (P=8.69E-05). The MS-
Park pair displayed no significant pathway overlap (P=0.184).
Among the KEGG results, the most highly significant pathway
overlap was between MS and RA (P=1.03E-13), followed by
T1D-RA (P=51.22E-12), T1D-Alz (P=5.91E-11), MS-T1D
(P=8.58E-10) etc. Yet, the analysis revealed that pathway
overlaps with Park could be due to chance, except for the MS-
Park pair (P=5.44E-03). Finally, the CGAP-BioCarta analysis
recognized T1D-Alz as the most significant association
(P=3.71E-12), followed by MS-RA (P=1.60E-11), MS-T1D
(P=2.16E-09), MS-Alz (P=1.60E-08) etc. To summarize, the p-
values based on KEGG and CGAP-BioCarta databases were
more significant among the disease pairs in the autoimmune
group, especially MS-RA. Moreover, on the basis of consistent
statistical results in all the three databases, the T1D-Alz pair can
be considered as the most significant disease pair in the context of
shared pathways.
Figure 4. Molecular vs. functional relatedness. A. Functional relatedness based on shared pathways. Statistical significance for each paired
analysis is given as relative to the database. The dotted line indicates the p-value threshold of 0.05. B. Shared pathways and interactors among
disease pairs.
doi:10.1371/journal.pone.0018660.g004
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consistent interactor sharing was present in several disease pairs.
Clearly, the more interactors were shared, the more common
pathways were expected. We critically evaluated this issue and
measured the Pearson’s correlation between the interactors and
the pathways (as reported by the three databases together) shared
among the disease pairs. Consistently, we observed that the
number of shared pathways was proportional to the number of
shared interactors in most cases (Figure 4B). However, the Alz
pairs with autoimmune diseases were not following this trend. The
overall Pearson’s correlation coefficient was 0.79, which increased
remarkably to 0.95 when Alz-autoimmune disease pairs were
excluded. These observations demonstrate that the number of
shared biological pathways among Alz and autoimmune diseases is
higher than expected on the basis of interactor sharing.
Finally, we ranked the associations among diseases based on the
statistical significance of shared pathways in each database (Table
S6). Scores starting from 1 were assigned from the highest
significant association to the lowest. Those with insignificant p-
values were assigned the rank 10. Then, we derived the cumulative
ranks for each disease pair by summing their ranks in the three
databases. As expected, T1D-Alz pair had the highest rank,
followed by the autoimmune disease pairs MS-RA and T1D-RA,
and then by MS-Alz and RA-Alz. All Park pairs scored very low.
These results were depicted in Figure 5 displaying a network
summary of relationships among the five diseases.
Altogether, the relationships among diseases identified at the
level of molecular interactions were found to be sustained at the
level of biological pathways, especially among autoimmune
diseases. Surprisingly, the same approaches evidenced strong
relatedness between Type 1 diabetes and Alzheimer’s disease.
Discussion
The reconstruction of the molecular framework hosting genetic
variants associated with susceptibility to a complex human
disorder has the potential to reveal the biological mechanisms
underlying that disease and to highlight similarities with other
diseases. Here we made a cross-disease comparison of autoim-
mune (T1D, RA) and neurodegenerative diseases (Park, Alz)
starting from the point of view of MS, as it presents both
autoimmune and neurodegenerative facets [3]. Indeed, several
nodes in the MS interactome interacted with the susceptibility
genes of the other four diseases, with a subset of MS interactors
making contact with both autoimmune and neurodegenerative
gwas-genes. These observations indicate that MS offers a
framework that, to a certain extent, can be shared by other
diseases. This is partly due to the fact that genetic susceptibility to
autoimmune disorders may be driven by variations in some
common genes [5,6]. In this regard, two scenarios have been
demonstrated. In the first case, the same variant may be involved
in susceptibility to distinct diseases. For instance, genetic variation
in the CLEC16A gene is associated with MS as well as T1D in the
Sardinian population [7]. In the second case, distinct variants in
the same gene predispose to distinct diseases, i.e. polymorphisms
in the IL2RA gene linked to MS or T1D susceptibility are different
[8,9].
Previous studies have shown that molecular relatedness between
distinct diseases may be found when searching for direct
relationships among gwas-genes [10,11] and that the analysis of
first-degree interactors may also lead to similar observations[1,2].
However, the advantage of the second approach compared to the
first one has never been specifically addressed. Our study shows
that the analysis of first-degree genetic interactomes may highlight
shared molecular frameworks undetectable at the gwas-gene level.
In fact, even when no interactions exist between gwas-genes,
several shared interactions may be found when considering the
genetic interactomes.
Furthermore, we elucidated the interactors linked to the gwas-
genes in all five diseases and the pathway enriched in each disease-
related interactome using the ToppGene suite. This tool contains
a meta-database of annotated pathway databases such as Panther,
KEGG, and CGAP-BioCarta. As the level of annotation and the
number of genes related to a pathway may vary among databases
[12], the outputs were not pooled but shown in relation to each
database. Although a few previous studies revealed enriched
biological pathways related to susceptibility genes in several
complex human disorders, including MS [10,13–15], no informa-
tion was available on pathways emerging from the global genetic
framework. In contrast, our study ascertained such issue in
multiple sclerosis as well as in four additional autoimmune or
neurodegenerative disorders. Independent pathway analyses
demonstrated several commonalities among distinct genetic
interactomes. Numerous immune related pathways were enriched
in autoimmune interactomes. This result was expected as many of
the susceptibility genes in RA, T1D and MS were immune related.
Notably, the pathways B-cell activation and T-cell activation appeared
in all autoimmune diseases. It is well known that both arms of
adaptive immunity greatly contribute to autoimmunity. Our data
suggest that the processes leading to alterations in immune
tolerance may be caused or sustained by the genetic framework,
and, hence, support the rationale for therapeutical approaches
Figure 5. Overall disease relatedness based on shared
pathways in the Panther, KEGG and CGAP-BioCarta databases.
Green nodes indicate the neurodegenerative disorders, whereas pink
nodes highlight the autoimmune diseases. The color of the edges
connecting the nodes reflects the shared pathway rank ranging from 3
(highest relatedness) to 30 (lowest relatedness).
doi:10.1371/journal.pone.0018660.g005
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Surprisingly, the same pathways appeared in Alzheimer’s disease.
The role of adaptive immunity in Alz so far remains under-
explored, however some studies suggest altered T cell phenotypes
and responses in such patients (reviewed by [16]). Interestingly,
regular use of anti-inflammatory drugs reduces the odds of
developing Alz [17,18]. Our observation that the Alz genetic
framework may have an impact on immune function questions the
classical distinction between inflammatory and non-inflammatory
diseases and supports the hypothesis that, even though the primary
insult is not inflammation but neurodegeneration, immunological
pathways play a role in the etiopathogenesis of Alzheimer’s disease
[19].
Most of the enriched pathways appeared in the category Growth
factor/Hormone signaling consistently among the three pathway
sources. Panther and CGAP-BioCarta reported the EGF related
pathway as enriched in Alz, T1D and RA or MS respectively,
while KEGG highlighted the ErbB signaling pathway in all four
diseases. EGF receptor belongs to the ErbB gene family.
Interestingly, EGF is decreased in liquor from multiple sclerosis
patients [20], while increased in the synovial fluid of RA patients,
where it may regulate the inflammatory process [21]. Moreover,
EGF promotes the release of amyloid precursor protein (APP)
[22], indicating that it might support amyloidogenesis in Alz.
Finally, downregulation of the EGF receptor signaling in
pancreatic islets causes diabetes [23]. Our data suggest that the
involvement of the EGF pathway in the pathogenesis of various
complex human disorders may be genetically determined. The
FGF signaling pathway appeared in two databases as enriched in
T1D and Alz. Interestingly, biological evidence links alterations in
this pathway to the two diseases, e.g. attenuation of FGF signaling
in mouse beta cells leads to diabetes [24], and aFGF levels in
liquor are increased in Alzheimer’s patients [25]. Insulin related
pathways were also enriched in T1D and Alz interactomes.
Obviously, the major defect in T1D is insulin deficiency caused by
the autoimmune attack against pancreatic b-cells. Accumulating
evidences indicate that alterations in insulin signaling may
contribute to Alz pathology (reviewed in [26]). Moreover, tau
phosphorylation is increased in diabetic animals [27], and mice
with combined APP overexpression and diabetes show exacerbat-
ed histological features of Alz [28]. Another interesting overlap is
the angiogenesis pathway shared exclusively between Alz and
T1D, especially if interpreted in relation to blood brain barrier
dysfunction due to increased vascular permeability induced by
hyperglycemia [29]. Further sharing of Growth factor/Hormone
signaling pathways between Alz and T1D strongly supports the
hypothesis of a genetic and functional link between these two
disorders.
CGAP-BioCarta highlighted TNF related pathways both in RA
and MS genetic interactomes. TNF is an inflammatory mediator
clearly involved in the RA and MS pathology [30,31]. Intrigu-
ingly, various biological compounds targeting TNF resulted
effective in RA treatment [32], while detrimental in multiple
sclerosis [33], indicating that TNF related pathways may play a
dual role in autoimmune diseases.
The Cell cycle and apoptosis category was almost dedicated to
autoimmune diseases. Such pathways regulate induction of
immune tolerance and, indeed, changes in the balance between
cell proliferation and death may lead to autoimmunity [34,35].
The same processes may be altered in neoplastic cells. Cancer
related pathways also consistently appeared enriched in the
KEGG database. Overall, our data indicate that the genetic
framework predisposing to complex human disorders may
contribute to changes in these basic cellular functions.
The paired comparisons of genetic interactomes allowed
measuring the degree of relatedness among the five disorders.
Sharing of interactors and pathways was highly significant among
the autoimmune group. This may be partly explained by the
genetic overlap between autoimmune diseases [5,6]. In fact,
among all autoimmune gwas-genes analyzed in our study, HLA-
DRB1 was associated with MS, T1D and RA, three genes
(PTPN22, PRKCQ, CTLA4) were shared between T1D and RA,
three (IL2RA, IL7R and CLEC16A) between MS and T1D, and
one more (CD40) between MS and RA. However, analyses at the
genetic network level also showed that several gwas-genes specific
for single pathologies converged at the interactome level, meaning
that, although the primary events may differ, the resulting
functional cascades may come together and lead to alterations in
the same pathways.
The most surprising observation was the strong correlation in
the T1D-Alz pair in terms of shared interactome and functions.
Moreover, this pair was found highly related by consistent
performances in the three distinct pathway databases. Clinical
and epidemiological data are available on associations between
T1D and Alz. Type 1 (and Type 2) diabetic patients present
deficits in numerous cognitive functions (reviewed in [36]) and
diabetes is a risk factor for Alz [37]. In addition, biological
evidence indicates that dysregulation of insulin metabolism may
affect amyloid-b accumulation and degradation [38].
In conclusion, in this article we provided an unprecedented
comparison among the genetic interactomes derived from genes
predisposing to five complex human disorders. The shift in the
network analysis from the gwas-genes to their first-degree
interactors made the detection of shared molecules possible even
when no interactions were present at the gwas-level. Furthermore,
it revealed strong molecular and functional relatedness among
autoimmune disorders. For example, the genetic interactomes
pertaining to autoimmune diseases converged on numerous routes
regarding immunity and growth factor signalling pathways. So,
network generation and functional annotation highlighted several
known pathogenic processes, indicating that changes in these
functions might be driven or sustained by the framework linked to
genetic susceptibility. Finally, the same tools underlined several
inherent relationships among the five diseases at the level of
genetic interactomes and biological pathways which went
unnoticed until now. Type 1 diabetes and Alzheimer’s disease
were emblematic in this respect, as they appeared the most closely
related disorders among all the disease pairs due to the extensive
sharing of interactors and functions.
Overall, this study established that the reconstruction of the
molecular framework hosting the genetic variants predisposing to
complex human disorders can significantly contribute to our
understanding of the biological functions linked to susceptibility
genes. Many of these in-silico results highly correlate with the
present experimental biology evidence, proving the reliability of
systems biology tools. Furthermore, the study revealed unexpected
genetic relationships, which await further biological validation.
Materials and Methods
Diseases and genetic association data
We collected genome wide association data related to five
human diseases (T1D, RA, Park, Alz and MS) from the GWAS
catalog (December 2009 version). The GWAS database is an
online resource comprising of all published genome-wide associ-
ation studies or meta-analyses of them, and provides information
regarding the gene, SNP variations and their statistical significance
in each study. We retrieved all the genes predisposing to each
Shared Interactomes among Complex Human Disorders
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205) of the database.
The list of genes associated with each disease is summarized in
Table 1 and the detailed records about each study such as sample
size, journal name, authors, site of polymorphism etc. are
summarized in the Table S1.
Interactome analysis
To derive the list of interacting partners of the gwas-genes, we
used the VisANT tool (December 2009 version) [39], a web-
enabled program for construction, visualization, and analysis of
molecular and higher order networks based on functional and
physical relations of the genesets. Further, VisANT retrieves the
interaction information from databases such as BIND, MIPS,
Biogrid, HPRD and CAGT. The lists of interactors are given in
Table S3. The statistical significances for the interactor overlap
among disease pairs were calculated using a hypergeometric test.
In order to compensate the eventual biases in database annotation,
we calculated the interactor score through the normalization of the
observed/expected ratio. In the VisANT database there were
93684 interactions among 12888 Homo sapiens genes, resulting in
an average of 7.26 interactions per gene (VisANT interaction
ratio). This ratio was used for normalization, as follows:
Disease interaction ratio = No. of interactions/No. of gwas-
genes.
Normalization factor = Disease interaction ratio/VisANT
interaction ratio.
Paired normalization factor = (Disease1 normalization factor) x
(Disease2 normalization factor).
Observed = No. of interactors shared within a disease pair.
Expected = (No. of interactors in disease1/12888) x (No. of
interactors in disease2).
Interactor score = (Observed/Expected) x (Paired normaliza-
tion factor).
Pathway enrichment study
We chose the ToppGene suite for determination of pathways
enriched in the genetic interactomes. At the time of analysis, this
tool maintained a meta-database of pathway information derived
from KEGG (update: June 2009), Panther (update information not
available),CGAP-BioCarta (update:August2009).Theanalysiswas
performed with the stringent criteria of Bonferroni corrected p-
value cut-off 0.05 in all cases. The combined p-values were
calculated for the shared pathways among diseases using Fisher’s
method [40].
Supporting Information
Table S1 Detailed records about the studies in the GWAS
catalog used in our analyses.
(XLS)
Table S2 Overlap of MS genetic interactome with genes
predisposing to other neurodegenerative or autoimmune diseases.
(XLS)
Table S3 List of the gwas genes and their interactors.
(XLS)
Table S4 Shared interactors in disease pairs.
(XLS)
Table S5 Statistical significances for interactor sharing and
interactor scores.
(XLS)
Table S6 Statistical significances for pathway sharing and
ranking of disease associations.
(XLS)
Table S7 List of shared pathways in disease pairs.
(XLS)
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